2cureX AB (publ) (STO:2CUREX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.280
-0.100 (-7.25%)
Jan 21, 2026, 5:23 PM CET
255.56%
Market Cap34.64M
Revenue (ttm)1.98M
Net Income (ttm)-26.35M
Shares Out25.10M
EPS (ttm)-1.50
PE Ration/a
Forward PEn/a
Dividend0.08 (4.43%)
Ex-Dividend DateJun 27, 2025
Volume465,963
Average Volume298,360
Open1.355
Previous Close1.380
Day's Range1.130 - 1.440
52-Week Range0.330 - 5.520
Beta1.46
RSI66.12
Earnings DateFeb 26, 2026

About 2cureX AB

2cureX AB (publ) operates as a medtech company in Europe. The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. In addition, the company offers research and consulting services. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 14
Stock Exchange Nasdaq Stockholm
Ticker Symbol 2CUREX
Full Company Profile

Financial Performance

In 2023, 2cureX AB's revenue was 2.95 million, a decrease of -12.53% compared to the previous year's 3.37 million. Losses were -32.52 million, 9.23% more than in 2022.

Financial Statements